Drug intelligence / Profile preview

selamectin

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Topical
01

Overview

Selamectin is a semi-synthetic avermectin antiparasitic and antihelminthic drug used topically in dogs and cats. It is primarily indicated for the prevention and treatment of heartworm disease (Dirofilaria immitis), flea infestations (Ctenocephalides spp.), ear mites (Otodectes cynotis), sarcoptic mange (Sarcoptes scabiei), certain ticks in dogs, as well as hookworms (Ancylostoma tubaeforme) and roundworms (Toxocara cati) in cats. Selamectin acts by binding to glutamate-gated chloride channels present in nerve and muscle cells of parasites. This increases chloride ion permeability across cell membranes leading to hyperpolarization, neuromuscular paralysis, impaired muscular contraction, and ultimately parasite death. Mammals lack these specific channels which confers a high safety margin for treated animals. The drug was developed by Pfizer (now Zoetis) and is not approved for human use[1][2][5][6][7].

Brand names
RevolutionParadyneStrongholdChanholdSelaridSenergy
02

Targets

GLRA1 (Glycine receptor subunit Alpha-1)GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on selamectin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on selamectin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call